ArticleOncoTargets and therapy2017
Prognostic value of high IMP3 expression in solid tumors: a meta-analysis.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Low GATA3 predicts worse survival in penile cancer.Scientific reports · 2025Article
- Combined detection of P53, Ki67, P504S, and IMP3: Diagnostic implications for gastric cancer and precursor lesions.World journal of gastrointestinal oncology · 2025Article
- Article
- A novel tumour enhancer function of Insulin-like growth factor II mRNA-binding protein 3 in colorectal cancer.Cell death & disease · 2023Article
- IMP3 Protein Overexpression Is Linked to Unfavorable Outcome in Laryngeal Squamous Cell Carcinoma.Cancers · 2021Article
- IMP3 protein is an independent prognostic factor of clinical stage II rectal cancer.Scientific reports · 2021Article
- Article
- Prognostic value of insulin-like growth factor 2 mRNA-binding protein 3 and vascular endothelial growth factor-A in patients with primary non-small-cell lung cancer.Oncology letters · 2019Article
- Prognostic significance of IMP-3 expression pattern in esophageal squamous cell carcinoma.Journal of thoracic disease · 2019Article
- Post-transcriptional Regulation of Colorectal Cancer: A Focus on RNA-Binding Proteins.Frontiers in molecular biosciences · 2019Review
- IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues.Oncology reports · 2018Article
- Invasive stratified mucin-producing carcinoma: a clinicopathological analysis of three cases.Cancer biology & therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccumulated studies have investigated the prognostic role of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in various cancers, but inconsistent and controversial results were obtained. Therefore, we performed a systematic review and meta-analysis to investigate the potential value of IMP3 in the prognostic prediction of human solid tumors. MATERIALS AND
methodsA systematic literature search in the electronic databases PubMed, Embase, Web of Science, and Cochrane library (updated to April 2016) was conducted to identify eligible studies. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for survival outcomes were calculated and gathered using STATA 12.0 software.
resultsA total of 53 studies containing 8,937 patients with solid tumors were included in this meta-analysis. High IMP3 expression was significantly associated with worse overall survival (OS) of solid tumors (HR =2.08, 95% CI: 1.80-2.42,
conclusionThe current evidence suggests that high IMP3 expression is associated with poor prognosis in most solid tumors. IMP3 is a potential valuable prognostic factor and might serve as a promising biomarker to guide clinical decisions in human solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.